Wayne B. Harris, MD

Associate Professor, Hematology & Medical Oncology

Emory University School of Medicine

Assistant Chief of Hematology & Medical Oncology

Atlanta VA Medical Center

Office: Atlanta VA Medical Center

Phone: (404) 778-3126

Email: wharr01@emory.edu


Dr. Wayne B. Harris obtained his Medical Degree from Loma Linda University in 1988. He subsequently completed three years of specialty training in Internal Medicine at Emory University in Atlanta. After completing a service obligation to the National Health Scholarship Corps in Chattanooga, TN, he returned to Emory where he completed three additional years of subspecialty training in Hematology and Oncology. He joined the faculty of the Winship Cancer Institute in 1998 where he has focused on developing new treatments for kidney cancer and prostate cancer through clinical trials and translational research. Dr. Harris is a member of the Core Committee for Genitourinary Oncology of the Eastern Cooperative Oncology Group. He also serves on the Loma Linda University Health Board of Trustees.

Dr. Harris established the Oncology Research Clinic at the Atlanta VA Medical Center so that veterans can choose to participate in clinical research studies. At Emory, he serves as principal investigator for clinical trials that focus on developing new treatments for renal cancer in both early and advanced stages of the disease.

Full Clinical Bio >>


The most urgent projected clinical need over the next five years for patients with kidney cancer is the development of effective therapies for patients whose disease no longer responds to currently available therapies. In spite of the fact that more than a half a dozen new targeted therapies have been introduced since 2005, none of these new drugs has the ability to cure kidney cancer. A second related need is for biomarkers of early response or resistance to therapy as none exists at present. Dr. Harris views biomarkers of inflammation as potential candidates in this regard and has developed the Emory Dynamic Model for Kidney Cancer on this basis. He is using this model to develop several investigator-initiated studies for which he will serve as the principal investigator at the Winship Cancer Institute and with the Eastern Cooperative Oncology Group.


Clinical Trials

View clinical trials at Winship Cancer Institute